# An Open Label Study of the Effects of Eculizumab in CD59 Deficiency

> **NCT01579838** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Hadassah Medical Organization** · enrollment: 5 (estimated)

## Conditions studied

- Chronic Hemolysis

## Interventions

- **DRUG:** Eculizumab

## Key facts

- **NCT ID:** NCT01579838
- **Lead sponsor:** Hadassah Medical Organization
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-02
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 5 (ESTIMATED)
- **Last updated:** 2012-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01579838

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01579838, "An Open Label Study of the Effects of Eculizumab in CD59 Deficiency". Retrieved via AI Analytics 2026-08-13 from https://api.ai-analytics.org/clinical/NCT01579838. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*